PMMI ProSource – Start Your Search
Check out our packaging and processing solutions finder, PMMI ProSource.

Batch 4.0

Food and pharmaceutical industries are adopting Industry 4.0 technologies to modernize manufacturing for both regulatory compliance and continuous improvement.

Pall is working on adding analytics into continuous single-use processes for biologic drug manufacturing. Source: Pall
Pall is working on adding analytics into continuous single-use processes for biologic drug manufacturing. Source: Pall

Earlier this year, the U.S. Food and Drug Administration (FDA) issued a draft guidance on quality considerations for pharmaceutical companies as they move to a continuous manufacturing process. The push to continuous processing in active pharmaceutical ingredients (APIs) and biologic drug manufacturing is predicated on the need to modernize the decades-old traditional “batch” manufacturing in which drugs are manufactured in multiple disconnected steps with testing delays and manual operations between them. Continuous manufacturing minimizes operational stops for a steady flow between processes that can ensure consistency, efficiency, scalability and a shortened supply chain that may even minimize drug shortages.

A move in this direction requires new kinds of equipment and technology. Pall, which provides high-tech filtration, separation and purification technologies for a variety of industries, is on the forefront of equipment that plays a key role in the development of life-saving drugs ranging from Ebola vaccines to cancer-curing monoclonal antibodies. Part of the effort of the organization is to help companies move to continuous bioprocessing, which will allow manufacturers to build flexible, multi-drug facilities.

But there are still some technology gaps in the continuous manufacturing process.

“We need new analytics and new automation technology,” says Loe Cameron, Pall’s Director of Analytics and Controls. “Because as you tie all of these individual unit operations together to act in an organized manner, you need real-time information for control strategies that balance the flow through the process. You no longer have time to take a sample and run to the analytics lab to make decisions. It all has to be online.”

There’s a similar need for new technologies to analyze and track data in the food and beverage industry given FDA directives such as the Food Safety Modernization Act (FSMA), which outlines good manufacturing practices, hazard analysis, risk-based preventive controls and more to prevent foodborne illness.

“If there’s ever a pathogen in the food and an [FDA] auditor comes in for the data, if [the company] can’t produce the data in 48 hours, they’ll get shut down,” says Travis Cox, Co-Director of Sales Engineering at Inductive Automation. That could mean losing millions of dollars a day. “All because they didn’t have a digital strategy to capture that information automatically.”

Whether it’s regulatory pressure or a business requirement to keep up with consumer needs for new medicine or demands for a variety of food products and packaging, the movement to modernize manufacturing has made its way to pharma and food industries. It’s actually an Industry 4.0 initiative that has hit these industry segments with the most important element being access to information and real-time analytics.

“Where Industry 4.0 comes into play in these industries is in accessing intelligent devices and coming up with intelligent analytics to help drive value back into the process, whether it is a higher throughput or quality to maintain competitiveness,” says Dan UpDyke, Market Development Manager for Consumer Packaged Goods (CPG) and Life Sciences Industries at Rockwell Automation.

Though the basic core principles of Industry 4.0 apply (modularization, data exchange, cloud and cognitive computing), it is how Industry 4.0 technologies and practices are implemented that is important because they need to be compliant with the requirements of the particular industry.

Pharma 4.0

In biotech, there are many monoclonal antibodies that are coming off patent, which means there is more activity around biosimilars coming into the space. Biosimilars—almost identical copies of an original product manufactured by a different company—are influenced by the manufacturing process that takes place.

“There are so many specific things that impact how a biosimilar works in the end,” Cameron says. “As things come off patent and biosimilar development increases, we are seeing a lot of people think about the process more deeply.”

To that end, analytics need to be directly tied to the process and need to be delivered fast enough to establish control, Cameron says, noting that Pall is working on adding analytics into continuous single-use processes. “We are trying to find new analytical tools that are more online and purpose-built for this kind of paradigm,” she says.

Pall’s continuous process demo lab uses Inductive Automation’s Ignition to connect equipment and analytical tools. “It gets the data where it needs to go and feeds directly into the historian,” Cameron says. “Being able to quickly establish communication and prototype workflows saves us a lot of time as we are trying to develop new control strategies for continuous.”